Recombinant CD22 (Epratuzumab Biosimilar) 抗体
This anti-CD22 (Epratuzumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting CD22 (Epratuzumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant CD22 (Epratuzumab Biosimilar) 抗体 (ABIN7795108)
抗原
CD22 (Epratuzumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Epratuzumab Biosimilar, Endotoxin 0.05 EU/mg
-
产品特性
- Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- Less than 0.5 EU/mg of protein as determined by LAL method
-
免疫原
- Human CD22
-
-
anti-CD22 (Epratuzumab Biosimilar) antibody
适用: 人, Cynomolgus, 猕猴 FACS, BP, IP 宿主: 兔 Chimeric hL22 unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CD22 (Epratuzumab Biosimilar)
-
别名
- Epratuzumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
